These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1778855)

  • 21. Antibacterial activity and beta-lactamase stability of MDL 19,592, an oral cephalosporin.
    Yu KW; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(5):441-3. PubMed ID: 2515027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of cefdinir with beta-lactamases.
    Labia R; Morand A
    Drugs Exp Clin Res; 1994; 20(2):43-8. PubMed ID: 7924895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].
    Bauernfeind A; Jungwirth R; Schweighart S; Theopold M
    Infection; 1990; 18 Suppl 3():S155-67. PubMed ID: 2079378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.
    Neu HC; Chin NX; Labthavikul P
    Antimicrob Agents Chemother; 1984 Aug; 26(2):174-80. PubMed ID: 6333207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
    Neu HC
    Pediatr Infect Dis J; 1987 Oct; 6(10):958-62. PubMed ID: 3696836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of cefdinir (C1-983, FK482) to extended-spectrum plasmid-mediated beta-lactamases.
    Payne DJ; Amyes SG
    J Med Microbiol; 1993 Feb; 38(2):114-7. PubMed ID: 8429536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
    Johnson DM; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity and beta-lactamase stability of RU29246, the active metabolite of HR916B.
    Yu KW; Chin NX; Neu HC
    Eur J Clin Microbiol Infect Dis; 1992 Jul; 11(7):652-9. PubMed ID: 1396779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of a catechol-substituted cephalosporin, GR69153.
    Wise R; Andrews JM; Ashby JP; Thornber D
    Antimicrob Agents Chemother; 1991 Feb; 35(2):329-34. PubMed ID: 2024966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin.
    Guay DR
    Clin Ther; 2002 Apr; 24(4):473-89. PubMed ID: 12017394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial activity and beta-lactamase stability of BMY-28232, parent compound of an oral cephalosporin.
    Chin NX; Yu KW; Neu HC
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):841-6. PubMed ID: 2086221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.
    Jones RN; Thornsberry C; Barry AL
    Antimicrob Agents Chemother; 1984 Jun; 25(6):710-8. PubMed ID: 6611135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activity and beta-lactamase stability of SR 44337, a new long acting cephalosporin.
    Cooper MA; Andrews JM; Baldwin DR; Thornber D; Wise R
    J Antimicrob Chemother; 1991 Aug; 28(2):229-37. PubMed ID: 1778854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir.
    Payne DJ; Amyes SG
    Drugs Exp Clin Res; 1992; 18(6):225-31. PubMed ID: 1478161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of a new broad-spectrum, beta-lactamase-stable oral cephalosporin, cefixime, in comparison with other drugs, against Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Streptococcus pneumoniae.
    Stefani S; Pellegrino MB; D'Amico G; Privitera A; Privitera O; Maccarrone G; Russo G; Nicoletti G
    Chemotherapy; 1992; 38(1):36-45. PubMed ID: 1618002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative microbiological activity and pharmacokinetics of cefprozil.
    Wise R
    Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):839-45. PubMed ID: 7889957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of cefcanel versus other oral cephalosporins.
    Chin NX; Gu JW; Neu HC
    Eur J Clin Microbiol Infect Dis; 1991 Aug; 10(8):676-82. PubMed ID: 1748125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antibacterial effect of cefixime in the presence of the type of beta-lactamases produced by Enterobacteriaceae].
    Philippon A; Jarlier V; Legrand P; Fournier G; Nicolas MH; Duval J
    Presse Med; 1989 Oct; 18(32):1560-6. PubMed ID: 2530532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.